BioTheranostics, a provider of molecular diagnostic solutions for cancer, has received a positive coverage decision and in-network provider status from Tufts Health Plan for its CancerType ID molecular cancer classifier. CancerType ID predicts tumor type in patients with metastatic cancers.
“With metastatic cancer, achieving diagnostic certainty is critical to optimize site-directed therapies that reduce costs and avoid ineffective therapies for both patients and payers,” Richard Ding, president and CEO of BioTheranostics, said in a statement. “This announcement is part of our efforts to work with payers across the country to make this important diagnostic test available to clinicians and cancer patients, helping to support personalized medicine with the goal of improving outcomes.”
BioTheranostics, 877-886-6739